Schizophrenia Relapse on a CTO: Case Review | MDster You are offline Back online! [ ](/) Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Case Discussion ](https://mdster.com/blog?category=case-discussion) 4. Schizophrenia Relapse on a CTO: Insight, Cannabis, and LAI Strategy [ Case Discussion ](https://mdster.com/blog?category=case-discussion) Schizophrenia Relapse on a CTO: Insight, Cannabis, and LAI Strategy ===================================================================== A board-focused case discussion on relapse risk, legal thresholds, depot pharmacology, and side-effect driven nonadherence [ MDster Editorial Team ](https://mdster.com/about) · Mar 24, 2026 · 7 min read · 53 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Psychiatry ](https://mdster.com/blog?tag=psychiatry) [ Schizophrenia ](https://mdster.com/blog?tag=schizophrenia) [ Community Treatment Order ](https://mdster.com/blog?tag=community-treatment-order) [ Long-Acting Injectables ](https://mdster.com/blog?tag=long-acting-injectables) [ Psychosis ](https://mdster.com/blog?tag=psychosis) [ Psychiatry Boards ](https://mdster.com/blog?tag=psychiatry-boards) ![Schizophrenia Relapse on a CTO: Insight, Cannabis, and LAI Strategy](https://mdster.com/storage/blog/01KMSZDJDZ86408T6E7AJTS0JA.jpg) Share this article Share this post Three weeks of nocturnal pacing, muttering, irritability, and self-neglect in a man with chronic schizophrenia who has missed a monthly haloperidol decanoate injection should make you think “early relapse with narrowing time to act,” not merely “noncompliance.” As of **March 24, 2026**, NICE guideline **CG178** remains current and was last reviewed on **July 29, 2025**. Haloperidol decanoate does not disappear abruptly after a missed dose: plasma levels rise slowly after injection, peak at about 6 days, and then fall with an apparent half-life of about 3 weeks, which explains why relapse after a missed depot often evolves over weeks rather than hours. [\[1\]](#cite-1 "Reference [1]") Framing the relapse ------------------- The leading diagnosis is **schizophrenia relapse driven by missed LAI treatment, impaired insight, and cannabis use**. The positive urine drug screen matters, but in a patient with a 10-year schizophrenia history it is more useful to think in terms of **cannabis-associated exacerbation** than a pure substance-induced psychosis unless the chronology strongly supports the latter. NICE advises that suspected relapse should trigger the crisis plan and reassessment for substance use, medication adherence, side effects, and physical or organic contributors to psychosis. [\[2\]](#cite-2 "Reference [2]") Working formulationWhy it stays on the listRelapse of schizophreniaMissed depot, emerging positive symptoms, poor self-care, prior severe relapsesCannabis-associated worseningPositive screen, known association with relapse and functional declineSubstance-induced psychosisLess likely, but temporal relationship and other substances must be checkedMedication adverse effects driving refusalHyperprolactinemia and possible EPS can erode adherence In the OPTiMiSE cohort, cannabis use **preceded** worsening and increased relapse risk even among patients who were otherwise compliant with antipsychotics; continued use has also been linked with more positive symptoms and rehospitalization. For boards, the exam point is not that cannabis “causes everything,” but that it meaningfully worsens course in a patient who is already drifting off treatment. [\[3\]](#cite-3 "Reference [3]") Insight, ethics, and the CTO ---------------------------- His statement that the injections are “poison,” coupled with denial of illness, captures the classic triad of impaired clinical insight: **lack of awareness of illness, failure to relabel symptoms as pathological, and lack of recognition of the need for treatment**. That distinction matters because disagreement with treatment is not the same as incapacity or lack of insight; here, however, the phenomenology points strongly to both poor insight and active psychotic interpretation of care. [\[4\]](#cite-4 "Reference [4]") The ethical tension is the familiar one: coercion risks damaging alliance, but under-treatment risks predictable deterioration, carer exhaustion, and eventual greater restriction. NICE explicitly frames transition planning around the **least restrictive setting available**, while still emphasizing clear explanation, advocacy, and therapeutic engagement to reduce the person’s sense of coercion. In England and Wales, continued supervised community treatment requires a mental disorder, a need for medical treatment, necessity for health or safety or protection of others, appropriate treatment availability, and the ongoing need for recall power. [\[5\]](#cite-5 "Reference [5]") Consequently, the next step is not an argument at the injection room door. It is **parallel processing**: de-escalate, assess immediate risk, document deterioration and insight, and decide whether CTO recall criteria are now met. Under the Mental Health Act framework, recall is justified when hospital treatment is required and failing to recall would create risk of harm; once recalled, the CTO can be revoked if detention criteria are again satisfied. Clinically, forced treatment should be a hospital-based, least restrictive, legally authorized intervention, not an improvised community confrontation. [\[6\]](#cite-6 "Reference [6]") > **Clinical Pearl:** A missed LAI dose buys time, not safety. Use that pharmacokinetic tail to assess relapse, side effects, substance use, and whether recall is now necessary. [\[7\]](#cite-7 "Reference [7]") Why the depot and the prolactin both matter ------------------------------------------- Board candidates should be precise about the pharmacology. Haloperidol decanoate is a **decanoate ester in sesame oil**, producing slow release and a prolonged elimination phase. That blunts the abrupt fall in D2 blockade seen after sudden oral discontinuation, which is why relapse may be delayed enough for community teams to re-engage the patient. But the same prolonged exposure means side effects can remain clinically relevant even when the patient is drifting off schedule. [\[7\]](#cite-7 "Reference [7]") His prolactin of **850 mIU/L** is not just a laboratory footnote. Dopamine normally tonically inhibits prolactin release; antipsychotic **D2 blockade at lactotrophs** removes that inhibition. The high-yield move is to ask specifically about libido, erectile dysfunction, gynecomastia, galactorrhea, menstrual or fertility symptoms where relevant, and whether those symptoms are feeding his refusal. Management is symptom-driven: confirm the pattern, exclude non-drug causes if the picture is atypical, then consider dose reduction, substitution with a prolactin-sparing antipsychotic, or adjunctive aripiprazole while balancing relapse risk. [\[8\]](#cite-8 "Reference [8]") Clinical application -------------------- The mother’s exhaustion is clinically important, not incidental. NICE recommends **carer-focused education and support** early, and **family intervention** for families in close contact with the patient, especially when relapse risk is high. In practice, this is one of the most underused relapse-prevention tools in chronic psychosis. If the team focuses only on the depot and ignores the household burden, the next relapse is often already being incubated. [\[2\]](#cite-2 "Reference [2]") Long-term adherence here will not be restored by legal compulsion alone. Once the acute phase is contained, the more durable plan is to revisit antipsychotic choice, address the meaning of the injection in his delusional framework, treat cannabis use as a relapse amplifier, and reintroduce structured psychological work such as CBT for psychosis plus family intervention. NICE recommends combining antipsychotic treatment with psychological interventions during acute recurrence and in ongoing care. [\[2\]](#cite-2 "Reference [2]") Key Points for Board Exams -------------------------- - **Poor insight in schizophrenia** is best framed as impaired awareness of illness, impaired relabeling of symptoms, and impaired recognition of the need for treatment. [\[4\]](#cite-4 "Reference [4]") - **CTO maintenance** depends on ongoing disorder, treatment need, risk-based necessity, treatment availability, and the need for recall power; least-restrictive practice still applies. [\[9\]](#cite-9 "Reference [9]") - **Missed LAI doses** do not produce the same immediate pharmacologic drop seen with oral nonadherence; haloperidol decanoate has an apparent half-life of about 3 weeks. [\[7\]](#cite-7 "Reference [7]") - **Cannabis use** meaningfully worsens relapse risk and can precede deterioration even when antipsychotic adherence is otherwise reasonable. [\[3\]](#cite-3 "Reference [3]") - **Haloperidol-associated hyperprolactinemia** reflects D2 blockade removing tonic dopaminergic inhibition of prolactin release; management starts with symptom assessment, then medication strategy. [\[8\]](#cite-8 "Reference [8]") - **Family intervention and carer support** are relapse-prevention interventions, not optional extras. [\[2\]](#cite-2 "Reference [2]") Conclusion ---------- This case is classic board psychiatry because the answer is never just “give the depot.” The real task is to recognize an evolving relapse, understand why the patient is refusing, use the CTO lawfully and proportionately, and treat side effects, cannabis use, and caregiver burden as part of the same illness trajectory. [\[6\]](#cite-6 "Reference [6]") References (13) ------------------- 1. 1. [ www.nice.org.uk/Guidance/CG178 ](https://www.nice.org.uk/Guidance/CG178) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ www.nice.org.uk/guidance/cg178/chapter/rec ](https://www.nice.org.uk/guidance/cg178/chapter/rec) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ Schoeler T, et al. Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Data From the OPTIMISE Study. Schizophrenia Bulletin. 2023 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC10318873/) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ pmc.ncbi.nlm.nih.gov/articles/PMC4269286 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC4269286/) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ www.nice.org.uk/guidance/NG53/chapter/recommendations ](https://www.nice.org.uk/guidance/NG53/chapter/recommendations) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ www.legislation.gov.uk/ukpga/2007/12/pdfs/ukpga\_20070012\_en.pdf ](https://www.legislation.gov.uk/ukpga/2007/12/pdfs/ukpga_20070012_en.pdf) [↩](#cite-ref-6-1 "Back to text") 7. 7. [ DailyMed. Haloperidol Decanoate Injection prescribing information ](https://www.dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=8ffac6fb-1702-40d6-b085-152d24673cbd&type=pdf) [↩](#cite-ref-7-1 "Back to text") 8. 8. [ Wadoo O, et al. Hyperprolactinaemia: A guide for psychiatrists. BJPsych Advances. 2017 ](https://www.cambridge.org/core/journals/bjpsych-advances/article/hyperprolactinaemia-a-guide-for-psychiatrists/E8F6C388532F0A7734EF18F4EE911F02) [↩](#cite-ref-8-1 "Back to text") 9. 9. [ www.gov.uk/guidance/appeal-a-community-treatment-order ](https://www.gov.uk/guidance/appeal-a-community-treatment-order) [↩](#cite-ref-9-1 "Back to text") 10. 10. [ NICE Guideline CG178: Psychosis and schizophrenia in adults: prevention and management ](https://www.nice.org.uk/guidance/cg178) 11. 11. [ NICE Guideline NG53: Transition between inpatient mental health settings and community or care home settings ](https://www.nice.org.uk/guidance/ng53/chapter/recommendations) 12. 12. [ Department of Health and Social Care. Mental Health Act 1983: Code of Practice ](https://www.gov.uk/government/publications/code-of-practice-mental-health-act-1983) 13. 13. [ Melmed S, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011 ](https://www.endocrine.org/clinical-practice-guidelines/hyperprolactinemia) Keep going Build momentum in Psychiatry with a focused study pathway ----------------------------------------------------------- - Exam‑style questions for Psychiatry - Smart review to target weak topics - Progress tracking that keeps you accountable [ Start your free trial ](https://mdster.com/user/dashboard) [ Explore Psychiatry ](https://mdster.com/speciality/psychiatry) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features. No commitment. Cancel anytime. [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() Related Posts ------------- [ ![Neonatal Septic Shock in the ED: A High-Yield Case Discussion](https://mdster.com/storage/blog/images/neonatal-septic-shock-in-the-ed-a-high-yield-case-discussion.jpg) Case Discussion ### Neonatal Septic Shock in the ED: A High-Yield Case Discussion An ill 18-day-old with fever, lethargy, shock, and hypoglycemia demands parallel resuscitation and sepsis management. This case reviews ED priorities, LP timing, antibiotics, HSV coverage, and board pearls. 6 min read 0 comments ](https://mdster.com/blog/neonatal-septic-shock-in-the-ed-a-high-yield-case-discussion) [ ![How to Pass the American Board of Psychiatry and Neurology (Initial Certification in Psychiatry)](https://mdster.com/storage/blog/images/how-to-pass-the-american-board-of-psychiatry-and-neurology-initial-certification-in-psychi.jpg) Study Tips ### How to Pass the American Board of Psychiatry and Neurology (Initial Certification in Psychiatry) Preparing for the ABPN Psychiatry boards? Use this practical, exam-specific plan to prioritize high-yield topics, train for linked-item sets, and study efficiently. 6 min read 0 comments ](https://mdster.com/blog/how-to-pass-the-american-board-of-psychiatry-and-neurology-initial-certification-in-psychi) [ ![Repaired Tetralogy of Fallot in Pregnancy: A Case Discussion](https://mdster.com/storage/blog/images/repaired-tetralogy-of-fallot-in-pregnancy-a-case-discussion.jpg) Case Discussion ### Repaired Tetralogy of Fallot in Pregnancy: A Case Discussion A high-yield case discussion on third-trimester decompensation in repaired tetralogy of Fallot, emphasizing right ventricular failure, delivery planning, and postpartum risk. 4 min read 0 comments ](https://mdster.com/blog/repaired-tetralogy-of-fallot-in-pregnancy-a-case-discussion) [ ](/) Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) ### Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) ### Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) ### Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept